Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Notes Payables (2022 - 2024)

Mereo BioPharma (MREO) has disclosed Notes Payables for 2 consecutive years, with $5.5 million as the latest value for Q4 2024.

  • On a quarterly basis, Notes Payables changed N/A to $5.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $5.5 million, a N/A change, with the full-year FY2024 number at $5.5 million, changed N/A from a year prior.
  • Notes Payables was $5.5 million for Q4 2024 at Mereo BioPharma, roughly flat from $5.6 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $13.3 million in Q4 2022 to a low of $4.6 million in Q1 2024.